• 1

    JemalASiegelRXuJWardE. Cancer Statistics, 2010. CA Cancer J Clin2010:277-300.

  • 2

    FaderlSTalpazMEstrovZ. The biology of chronic myeloid leukemia. N Engl J Med1999;341:164-172.

  • 3

    RadichJPDaiHMaoM. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A2006;103:2794-2799.

    • Search Google Scholar
    • Export Citation
  • 4

    SawyersCL. Chronic myeloid leukemia. N Engl J Med1999;340:1330-1340.

  • 5

    JamiesonCHMAillesLEDyllaSJ. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med2004;351:657-667.

    • Search Google Scholar
    • Export Citation
  • 6

    SokalJCoxEBaccaraniM. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood1984;63:789-799.

  • 7

    HasfordJPfirrmannMHehlmannR. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst1998;90:850-858.

    • Search Google Scholar
    • Export Citation
  • 8

    JabbourECortesJEGilesFJ. Current and emerging treatment options in chronic myeloid leukemia. Cancer2007;109:2171-2181.

  • 9

    StoneRM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist2004;9:259-270.

  • 10

    KantarjianHSawyersCHochhausA. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med2002;346:645-652.

    • Search Google Scholar
    • Export Citation
  • 11

    HochhausADrukerBSawyersC. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood2008;111:1039-1043.

    • Search Google Scholar
    • Export Citation
  • 12

    O'BrienSGGuilhotFLarsonRA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med2003;348:994-1004.

    • Search Google Scholar
    • Export Citation
  • 13

    DrukerBJGuilhotFO'BrienSG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006;355:2408-2417.

    • Search Google Scholar
    • Export Citation
  • 14

    DeiningerMO'BrienSGGuilhotF. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood2009;114:Abstract 1126.

    • Search Google Scholar
    • Export Citation
  • 15

    KantarjianHMTalpazMO'BrienS. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood2006;108:1835-1840.

    • Search Google Scholar
    • Export Citation
  • 16

    RoyLGuilhotJKrahnkeT. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood2006;108:1478-1484.

    • Search Google Scholar
    • Export Citation
  • 17

    GuilhotFDrukerBLarsonRA. High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica2009;94:1669-1675.

    • Search Google Scholar
    • Export Citation
  • 18

    SchifferCA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med2007;357:258-265.

  • 19

    BermanENicolaidesMMakiRG. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med2006;354:2006-2013.

  • 20

    Quintas-CardamaAKantarjianHO'BrienS. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer2004;100:2592-2597.

    • Search Google Scholar
    • Export Citation
  • 21

    CortesJO'BrienSQuintasA. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer2004;100:2396-2402.

    • Search Google Scholar
    • Export Citation
  • 22

    SantosFPAlvaradoYKantarjianH. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer2011;117:982-991.

    • Search Google Scholar
    • Export Citation
  • 23

    KerkelaRGrazetteLYacobiR. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med2006;12:908-916.

  • 24

    AtallahEDurandJBKantarjianHCortesJ. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood2007;110:1233-1237.

    • Search Google Scholar
    • Export Citation
  • 25

    HughesTPBranfordSWhiteDL. Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood2008;112:3965-3973.

    • Search Google Scholar
    • Export Citation
  • 26

    KantarjianHTalpazMO'BrienS. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood2004;103:2873-2878.

    • Search Google Scholar
    • Export Citation
  • 27

    CortesJEKantarjianHMGoldbergSL. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses. J Clin Oncol2009;27:4754-4759.

    • Search Google Scholar
    • Export Citation
  • 28

    CastagnettiFPalandriFAmabileM. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. Blood2009;113:3428-3434.

    • Search Google Scholar
    • Export Citation
  • 29

    BaccaraniMRostiGCastagnettiF. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood2009;113:4497-4504.

    • Search Google Scholar
    • Export Citation
  • 30

    CortesJEBaccaraniMGuilhotF. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol2010;28:424-430.

    • Search Google Scholar
    • Export Citation
  • 31

    HehlmannRLausekerMJung-MunkwitzS. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol2011;29:1634-1642.

    • Search Google Scholar
    • Export Citation
  • 32

    ShahNPTranCLeeFY. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science2004;305:399-401.

  • 33

    TalpazMShahNPKantarjianH. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med2006;354:2531-2541.

  • 34

    HochhausAKantarjianHMBaccaraniM. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood2007;109:2303-2309.

    • Search Google Scholar
    • Export Citation
  • 35

    MauroMJBaccaraniMCervantesF. Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C) [abstract]. J Clin Oncol2008;26:Abstract 7009.

    • Search Google Scholar
    • Export Citation
  • 36

    BaccaraniMRostiGSaglioG. Dasatinib time to and durability of major and complete cytogenetic response (MCyR and CCyR) in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood2008;112:Abstract 450.

    • Search Google Scholar
    • Export Citation
  • 37

    GuilhotFApperleyJKimDW. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood2007;109:4143-4150.

    • Search Google Scholar
    • Export Citation
  • 38

    ApperleyJFCortesJEKimDW. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol2009;27:3472-3479.

    • Search Google Scholar
    • Export Citation
  • 39

    CortesJRousselotPKimDW. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood2007;109:3207-3213.

    • Search Google Scholar
    • Export Citation
  • 40

    CortesJKimDWRaffouxE. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia2008;22:2176-2183.

    • Search Google Scholar
    • Export Citation
  • 41

    Quintas-CardamaAHanXKantarjianHCortesJ. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood2009;114:261-263.

    • Search Google Scholar
    • Export Citation
  • 42

    Quintas-CardamaAKantarjianHO'BrienS. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol2007;25:3908-3914.

    • Search Google Scholar
    • Export Citation
  • 43

    MustjokiSEkblomMArstilaTP. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia2009;23:1398-1405.

    • Search Google Scholar
    • Export Citation
  • 44

    PorkkaKKhouryHJPaquetteRL. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer2010;116:377-386.

    • Search Google Scholar
    • Export Citation
  • 45

    SchifferCACortesJESaglioG. Association of lymphocytosis following treatment with dasatinib with response and outcome [abstract]. J Clin Oncol2010;28:Abstract 6553.

    • Search Google Scholar
    • Export Citation
  • 46

    SchifferCACortesJESaglioG. Lymphocytosis following first-line treatment for CML in chronic phase with dasatinib is associated with improved responses: a comparison with imatinib [abstract]. Blood2010;116:Abstract 358.

    • Search Google Scholar
    • Export Citation
  • 47

    ShahNPKantarjianHMKimDW. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol2008;26:3204-3212.

    • Search Google Scholar
    • Export Citation
  • 48

    ShahNPKimDWKantarjianH. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica2010;95:232-240.

    • Search Google Scholar
    • Export Citation
  • 49

    ShahNPCortesJESchifferCA. Five-year follow-up of patients with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib [abstract]. J Clin Oncol2011;29 (Suppl 15):Abstract 6512.

    • Search Google Scholar
    • Export Citation
  • 50

    KantarjianHCortesJKimDW. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood2009;113:6322-6329.

    • Search Google Scholar
    • Export Citation
  • 51

    SaglioGHochhausAGohYT. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer2010;116:3852-3861.

    • Search Google Scholar
    • Export Citation
  • 52

    CortesJEJonesDO'BrienS. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol2010;28:398-404.

    • Search Google Scholar
    • Export Citation
  • 53

    KantarjianHShahNPHochhausA. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med2010;362:2260-2270.

    • Search Google Scholar
    • Export Citation
  • 54

    KantarjianHShahNPCortesJE. Dasatinib or imatinib (IM) in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): two-year follow-up from DASISION [abstract]. J Clin Oncol2011;29 (Suppl 15):Abstract 6510.

    • Search Google Scholar
    • Export Citation
  • 55

    RadichJPKopeckyKJKamel-ReidS. A randomized phase II trial of dasatinib 100 mg vs imatinib 400 mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup trial [abstract]. Blood2010;116:Abstract LBA-6.

    • Search Google Scholar
    • Export Citation
  • 56

    KantarjianHGilesFWunderleL. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med2006;354:2542-2551.

    • Search Google Scholar
    • Export Citation
  • 57

    KantarjianHMGilesFGattermannN. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood2007;110:3540-3546.

    • Search Google Scholar
    • Export Citation
  • 58

    KantarjianHMGilesFJBhallaKN. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood2011;117:1141-1145.

    • Search Google Scholar
    • Export Citation
  • 59

    le CoutrePOttmannOGGilesF. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood2008;111:1834-1839.

    • Search Google Scholar
    • Export Citation
  • 60

    le CoutrePDGilesFHochhausA. Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study [abstract]. J Clin Oncol2009;27 (Suppl 15):Abstract 7057.

    • Search Google Scholar
    • Export Citation
  • 61

    GilesFJKantarjianHle CoutrePD. Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib [abstract]. J Clin Oncol2010;28 (Suppl 15):Abstract 6510.

    • Search Google Scholar
    • Export Citation
  • 62

    CortesJEJonesDO'BrienS. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol2010;28:392-397.

    • Search Google Scholar
    • Export Citation
  • 63

    RostiGPalandriFCastagnettiF. Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood2009;114:4933-4938.

  • 64

    SaglioGKimDWIssaragrisilS. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med2010;362:2251-2259.

  • 65

    LarsonRAKimDRostiG. Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd 24-month follow-up [abstract]. J Clin Oncol2011;29 (Suppl 15):Abstract 6511.

    • Search Google Scholar
    • Export Citation
  • 66

    AliROzkalemkasFKimyaY. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet2009;280:169-175.

    • Search Google Scholar
    • Export Citation
  • 67

    AlKindiSDennisonDPathareA. Imatinib in pregnancy. Eur J Haematol2005;74:535-537.

  • 68

    AultPKantarjianHO'BrienS. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol2006;24:1204-1208.

  • 69

    ChoudharyDRMishraPKumarR. Pregnancy on imatinib: fatal outcome with meningocele. Ann Oncol2006;17:178-179.

  • 70

    HeartinEWalkinshawSClarkRE. Successful outcome of pregnancy in chronic myeloid leukaemia treated with imatinib. Leuk Lymphoma2004;45:1307-1308.

    • Search Google Scholar
    • Export Citation
  • 71

    PrabhashKSastryPSBiswasG. Pregnancy outcome of two patients treated with imatinib. Ann Oncol2005;16:1983-1984.

  • 72

    PyeSMCortesJAultP. The effects of imatinib on pregnancy outcome. Blood2008;111:5505-5508.

  • 73

    RamasamyKHaydenJLimZ. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol2007;137:374-375.

    • Search Google Scholar
    • Export Citation
  • 74

    SeymourJFGriggAReynoldsJ. Two year data from a prospective safety study analyzing the consequences of imatinib mesylate inhibition of sensitive kinases other than bcr-abl in patients with previously untreated chronic phase CML [abstract]. Blood2006;108:Abstract 2147.

    • Search Google Scholar
    • Export Citation
  • 75

    CortesJO'BrienSAultP. Pregnancy outcomes among patients with chronic myeloid leukemia treated with dasatinib [abstract]. Blood2008;112:Abstract 3230.

    • Search Google Scholar
    • Export Citation
  • 76

    ConchonMSanabaniSSSerpaM. Successful pregnancy and delivery in a patient with chronic myeloid leukemia while on dasatinib therapy. Adv Hematol2010;2010:136252.

    • Search Google Scholar
    • Export Citation
  • 77

    OweiniHOtrockZKMahfouzRARBazarbachiA. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib [published online ahead of print May 15, 2010]. Arch Gynecol Obstet2011;283:133-134.

    • Search Google Scholar
    • Export Citation
  • 78

    ConchonMSanabaniSSBenditI. Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study. J Hematol Oncol2009;2:42.

    • Search Google Scholar
    • Export Citation
  • 79

    DeiningerMWO'BrienSGFordJMDrukerBJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol2003;21:1637-1647.

    • Search Google Scholar
    • Export Citation
  • 80

    GuoJQWangJYJArlinghausRB. Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients. Cancer Research1991;51:3048-3051.

    • Search Google Scholar
    • Export Citation
  • 81

    CortesJETalpazMBeranM. Philadelphia chromosome-negative chronic myelogenous leukemia with rearrangement of the breakpoint cluster region. Long-term follow-up results. Cancer1995;75:464-470.

    • Search Google Scholar
    • Export Citation
  • 82

    O'BrienSBermanEMooreJO. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw2011;9 (Suppl 2):S1-S25.

    • Search Google Scholar
    • Export Citation
  • 83

    LiptonJHKhoroshkoNGolenkovA. Phase II, randomized, multicenter, comparative study of peginterferon-alpha-2a (40 kD) (Pegasys) versus interferon alpha-2a (Roferon-A) in patients with treatment-naive, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma2007;48:497-505.

    • Search Google Scholar
    • Export Citation
  • 84

    MichalletMMaloiselFDelainM. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia2004;18:309-315.

    • Search Google Scholar
    • Export Citation
  • 85

    Gambacorti-PasseriniCZucchettiMRussoD. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res2003;9:625-632.

    • Search Google Scholar
    • Export Citation
  • 86

    LarsonRADrukerBJGuilhotF. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood2008;111:4022-4028.

    • Search Google Scholar
    • Export Citation
  • 87

    PicardSTitierKEtienneG. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood2007;109:3496-3499.

    • Search Google Scholar
    • Export Citation
  • 88

    AultPKantarjianHMBryanJ. Clinical use of imatinib plasma levels in patients with chronic myeloid leukemia (CML) [abstract]. Blood2008;112:Abstract 4255.

    • Search Google Scholar
    • Export Citation
  • 89

    ForrestDLTrainorSBrinkmanRR. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res2009;33:271-275.

    • Search Google Scholar
    • Export Citation
  • 90

    ThomasJWangLClarkREPirmohamedM. Active transport of imatinib into and out of cells: implications for drug resistance. Blood2004;104:3739-3745.

    • Search Google Scholar
    • Export Citation
  • 91

    WangLGiannoudisALaneS. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther2008;83:258-264.

    • Search Google Scholar
    • Export Citation
  • 92

    WhiteDLSaundersVADangP. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood2007;110:4064-4072.

    • Search Google Scholar
    • Export Citation
  • 93

    WhiteDLDangPEnglerJ. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol2010;28:2761-2767.

    • Search Google Scholar
    • Export Citation
  • 94

    GiannoudisADaviesALucasCM. Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood2008;112:3348-3354.

    • Search Google Scholar
    • Export Citation
  • 95

    HiwaseDKSaundersVHewettD. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer Res2008;14:3881-3888.

    • Search Google Scholar
    • Export Citation
  • 96

    DaviesAJordanidesNEGiannoudisA. Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia2009;23:1999-2006.

    • Search Google Scholar
    • Export Citation
  • 97

    WhiteDLSaundersVADangP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood2006;108:697-704.

    • Search Google Scholar
    • Export Citation
  • 98

    GorreMEMohammedMEllwoodK. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science2001;293:876-880.

    • Search Google Scholar
    • Export Citation
  • 99

    HochhausAKreilSCorbinAS. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia2002;16:2190-2196.

  • 100

    le CoutrePTassiEVarella-GarciaM. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood2000;95:1758-1766.

    • Search Google Scholar
    • Export Citation
  • 101

    ApperleyJF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol2007;8:1018-1029.

  • 102

    KhorashadJSde LavalladeHApperleyJF. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol2008;26:4806-4813.

    • Search Google Scholar
    • Export Citation
  • 103

    BranfordSRudzkiZWalshS. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood2003;102:276-283.

    • Search Google Scholar
    • Export Citation
  • 104

    NicoliniFECormSLeQH. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia2006;20:1061-1066.

    • Search Google Scholar
    • Export Citation
  • 105

    SoveriniSColarossiSGnaniA. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res2006;12:7374-7379.

    • Search Google Scholar
    • Export Citation
  • 106

    SoveriniSMartinelliGRostiG. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol2005;23:4100-4109.

    • Search Google Scholar
    • Export Citation
  • 107

    JabbourEKantarjianHJonesD. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia2006;20:1767-1773.

    • Search Google Scholar
    • Export Citation
  • 108

    JabbourEKantarjianHJonesD. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood2008;112:53-55.

    • Search Google Scholar
    • Export Citation
  • 109

    NicoliniFEHayetteSCormS. Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation. Haematologica2007;92:1238-1241.

    • Search Google Scholar
    • Export Citation
  • 110

    O'DwyerMEMauroMJKurilikG. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood2002;100:1628-1633.

    • Search Google Scholar
    • Export Citation
  • 111

    O'DwyerMEMauroMJBlasdelC. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood2004;103:451-455.

    • Search Google Scholar
    • Export Citation
  • 112

    MajlisASmithTLTalpazM. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol1996;14:196-203.

  • 113

    CortesJETalpazMGilesF. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood2003;101:3794-3800.

    • Search Google Scholar
    • Export Citation
  • 114

    VermaDKantarjianHShanJ. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy. Cancer2010;116:2673-2681.

    • Search Google Scholar
    • Export Citation
  • 115

    KantarjianHMTalpazMO'BrienS. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood2003;101:473-475.

    • Search Google Scholar
    • Export Citation
  • 116

    MarinDGoldmanJMOlavarriaEApperleyJF. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses. Blood2003;102:2702-2704.

    • Search Google Scholar
    • Export Citation
  • 117

    ZonderJAPembertonPBrandtH. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res2003;9:2092-2097.

    • Search Google Scholar
    • Export Citation
  • 118

    JabbourEKantarjianHMJonesD. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standarddose imatinib therapy. Blood2009;113:2154-2160.

    • Search Google Scholar
    • Export Citation
  • 119

    KantarjianHMLarsonRAGuilhotF. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer2009;115:551-560.

    • Search Google Scholar
    • Export Citation
  • 120

    KantarjianHPasquiniRHamerschlakN. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood2007;109:5143-5150.

    • Search Google Scholar
    • Export Citation
  • 121

    KantarjianHPasquiniRLevyV. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer2009;115:4136-4147.

    • Search Google Scholar
    • Export Citation
  • 122

    Quintas-CardamaACortesJ. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin Cancer Res2008;14:4392-4399.

    • Search Google Scholar
    • Export Citation
  • 123

    MarinDKaedaJSAndreassonC. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib. Cancer2005;103:1850-1855.

    • Search Google Scholar
    • Export Citation
  • 124

    Quintas-CardamaAKantarjianHGarcia-ManeroG. Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer2007;109:248-255.

    • Search Google Scholar
    • Export Citation
  • 125

    CortesJEKhouryHJCormS. Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: data from an ongoing phase II/III trial [abstract]. J Clin Oncol2009;27 (Suppl 15):Abstract 7008.

    • Search Google Scholar
    • Export Citation
  • 126

    WetzlerMHellmannALiptonJ. Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): data from an ongoing phase II trial [abstract]. J Clin Oncol2009;27(Suppl 15):Abstract 7027.

    • Search Google Scholar
    • Export Citation
  • 127

    KantarjianHSchifferCJonesDCortesJ. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood2008;111:1774-1780.

    • Search Google Scholar
    • Export Citation
  • 128

    HughesTPBranfordS. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology Am Soc Hematol Educ Program2009:477-487.

    • Search Google Scholar
    • Export Citation
  • 129

    RadichJP. How I monitor residual disease in chronic myeloid leukemia. Blood2009;114:3376-3381.

  • 130

    LandstromAPKetterlingRPKnudsonRATefferiA. Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia. Leuk Lymphoma2006;47:2055-2061.

    • Search Google Scholar
    • Export Citation
  • 131

    MuhlmannJThalerJHilbeW. Fluorescence in situ hybridization (FISH) on peripheral blood smears for monitoring Philadelphia chromosome-positive chronic myeloid leukemia (CML) during interferon treatment: a new strategy for remission assessment. Genes Chromosomes Cancer1998;21:90-100.

    • Search Google Scholar
    • Export Citation
  • 132

    Douet-GuilbertNMorelFLe CharpentierT. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res2004;24:2535-2539.

    • Search Google Scholar
    • Export Citation
  • 133

    SeongDCKantarjianHMRoJY. Hypermetaphase fluorescence in situ hybridization for quantitative monitoring of Philadelphia chromosome-positive cells in patients with chronic myelogenous leukemia during treatment. Blood1995;86:2343-2349.

    • Search Google Scholar
    • Export Citation
  • 134

    DewaldGWWyattWAJuneauAL. Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia. Blood1998;91:3357-3365.

    • Search Google Scholar
    • Export Citation
  • 135

    de LavalladeHApperleyJFKhorashadJS. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol2008;26:3358-3363.

    • Search Google Scholar
    • Export Citation
  • 136

    Quintas-CardamaACortesJEO'BrienS. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia. Cancer2009;115:2912-2921.

    • Search Google Scholar
    • Export Citation
  • 137

    JabbourEKantarjianHMShanJ. The achievement of an early complete cytogenetic response (CCyR) is a major determinant for outcome in patients (pts) with early chronic phase (CP) chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) [abstract]. Blood2010;116:Abstract 3429.

    • Search Google Scholar
    • Export Citation
  • 138

    BummTMullerCAl-AliHK. Emergence of clonal cytogenetic abnormalities in Ph-cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood2003;101:1941-1949.

    • Search Google Scholar
    • Export Citation
  • 139

    FeldmanENajfeldVSchusterM. The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylate. Exp Hematol2003;31:702-707.

    • Search Google Scholar
    • Export Citation
  • 140

    MedinaJKantarjianHTalpazM. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer2003;98:1905-1911.

    • Search Google Scholar
    • Export Citation
  • 141

    TerreCEclacheVRousselotP. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia2004;18:1340-1346.

    • Search Google Scholar
    • Export Citation
  • 142

    DeiningerMWCortesJPaquetteR. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer2007;110:1509-1519.

    • Search Google Scholar
    • Export Citation
  • 143

    JabbourEKantarjianHMAbruzzoLV. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood2007;110:2991-2995.

    • Search Google Scholar
    • Export Citation
  • 144

    KantarjianHMTalpazMCortesJ. Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia. Clin Cancer Res2003;9:160-166.

    • Search Google Scholar
    • Export Citation
  • 145

    BaccaraniMCortesJPaneF. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol2009;27:6041-6051.

    • Search Google Scholar
    • Export Citation
  • 146

    CrossNC. Standardisation of molecular monitoring for chronic myeloid leukaemia. Best Pract Res Clin Haematol2009;22:355-365.

  • 147

    BranfordSCrossNCPHochhausA. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia2006;20:1925-1930.

    • Search Google Scholar
    • Export Citation
  • 148

    HughesTDeiningerMHochhausA. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood2006;108:28-37.

    • Search Google Scholar
    • Export Citation
  • 149

    HughesTPKaedaJBranfordS. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med2003;349:1423-1432.

    • Search Google Scholar
    • Export Citation
  • 150

    PressRDLoveZTronnesAA. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood2006;107:4250-4256.

    • Search Google Scholar
    • Export Citation
  • 151

    PressRDGalderisiCYangR. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res2007;13:6136-6143.

    • Search Google Scholar
    • Export Citation
  • 152

    HughesTPHochhausABranfordS. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood2010;116:3758-3765.

    • Search Google Scholar
    • Export Citation
  • 153

    CortesJTalpazMO'BrienS. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res2005;11:3425-3432.

    • Search Google Scholar
    • Export Citation
  • 154

    IacobucciISaglioGRostiG. Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. Clin Cancer Res2006;12:3037-3042.

    • Search Google Scholar
    • Export Citation
  • 155

    PalandriFIacobucciISoveriniS. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. Clin Cancer Res2009;15:1059-1063.

    • Search Google Scholar
    • Export Citation
  • 156

    MarinDMilojkovicDOlavarriaE. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood2008;112:4437-4444.

    • Search Google Scholar
    • Export Citation
  • 157

    CervantesFLópez-GarridoPMonteroMI. Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. Haematologica2010;95:1317-1324.

    • Search Google Scholar
    • Export Citation
  • 158

    KantarjianHCortesJ. Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. J Clin Oncol2011;29:1512-1516.

    • Search Google Scholar
    • Export Citation
  • 159

    BranfordSRudzkiZParkinsonI. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood2004;104:2926-2932.

    • Search Google Scholar
    • Export Citation
  • 160

    WangLKnightKLucasCClarkR. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia. Haematologica2006;91:235-239.

    • Search Google Scholar
    • Export Citation
  • 161

    KantarjianHMShanJJonesD. Significance of rising levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) in complete cytogenetic response (CGCR) [abstract]. Blood2008;112:Abstract 445.

    • Search Google Scholar
    • Export Citation
  • 162

    PressRDWillisSGLaudadioJ. Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib. Blood2009;114:2598-2605.

    • Search Google Scholar
    • Export Citation
  • 163

    KantarjianHMShanJJonesD. Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response. J Clin Oncol2009;27:3659-3663.

    • Search Google Scholar
    • Export Citation
  • 164

    BranfordSMeloJVHughesTP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?Blood2009;114:5426-5435.

    • Search Google Scholar
    • Export Citation
  • 165

    JabbourEBranfordSSaglioG. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer2011;117:1800-1811.

    • Search Google Scholar
    • Export Citation
  • 166

    MullerMCCortesJEKimDW. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood2009;114:4944-4953.

    • Search Google Scholar
    • Export Citation
  • 167

    JabbourEKantarjianHMJonesD. Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood2008;112:4839-4842.

    • Search Google Scholar
    • Export Citation
  • 168

    SoveriniSColarossiSGnaniA. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica2007;92:401-404.

    • Search Google Scholar
    • Export Citation
  • 169

    HughesTSaglioGBranfordS. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol2009;27:4204-4210.

    • Search Google Scholar
    • Export Citation
  • 170

    SoveriniSGnaniAColarossiS. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood2009;114:2168-2171.

    • Search Google Scholar
    • Export Citation
  • 171

    TestoniNMarzocchiGLuattiS. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood2009;114:4939-4943.

    • Search Google Scholar
    • Export Citation
  • 172

    LimaLBernal-MizrachiLSaxeD. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer2011;117:1245-1252.

    • Search Google Scholar
    • Export Citation
  • 173

    AlvaradoYKantarjianHO'BrienS. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer2009;115:3709-3718.

    • Search Google Scholar
    • Export Citation
  • 174

    BrecciaMStagnoFVigneriP. Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up. Am J Hematol2010;85:375-377.

    • Search Google Scholar
    • Export Citation
  • 175

    KohYKimIYoonSS. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann Hematol2010;89:725-731.

    • Search Google Scholar
    • Export Citation
  • 176

    YeungDTOsbornMWhiteDL. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II trial [abstract]. Blood2010;116:Abstract 209.

    • Search Google Scholar
    • Export Citation
  • 177

    HochhausAMullerMCRadichJ. Dasatinib-associated major molecular responses are rapidly achieved in patients with chronic myeloid leukemia in chronic phase (CML-CP) following resistance, suboptimal response, or intolerance on imatinib [abstract]. Blood2008;112:Abstract 1095.

    • Search Google Scholar
    • Export Citation
  • 178

    NicoliniFEKimDWCeglarekB. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or --intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access In Clinical Trials) study [abstract]. Blood2009;114:Abstract 2201.

    • Search Google Scholar
    • Export Citation
  • 179

    YangASJillellaAMillerCB. Nilotinib-associated molecular responses achieved in chronic myeloid leukemia in chronic phase (CML-CP) patients with a suboptimal molecular response to imatinib [abstract]. Blood2009;114:Abstract 2206.

    • Search Google Scholar
    • Export Citation
  • 180

    TamCSKantarjianHGarcia-ManeroG. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood2008;112:516-518.

    • Search Google Scholar
    • Export Citation
  • 181

    MilojkovicDNicholsonEApperleyJF. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica2010;95:224-231.

    • Search Google Scholar
    • Export Citation
  • 182

    ShahNPCortesJESchifferCA. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily [abstract]. J Clin Oncol2010;28 (Suppl 15):Abstract 6512.

    • Search Google Scholar
    • Export Citation
  • 183

    BranfordSLawrenceRFletcherL. The initial molecular response of chronic phase cml patients treated with second generation ABL inhibitor therapy after imatinib failure can predict inadequate response and provide indications for rational mutation screening [abstract]. Blood2008;112:Abstract 331.

    • Search Google Scholar
    • Export Citation
  • 184

    BranfordSKimDWSoveriniS. Molecular response at 3 months on nilotinib therapy predicts response and long-term outcomes in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood2009;114:Abstract 3292.

    • Search Google Scholar
    • Export Citation
  • 185

    JabbourEKantarjianHO'BrienS. Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure. Blood2011;117:1822-1827.

    • Search Google Scholar
    • Export Citation
  • 186

    GargRJKantarjianHO'BrienS. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood2009;114:4361-4368.

    • Search Google Scholar
    • Export Citation
  • 187

    HochhausA. Advances in the treatment of haematological malignancies: optimal sequence of CML treatment. Ann Oncol2007;18 (Suppl 9):ix58-63.

    • Search Google Scholar
    • Export Citation
  • 188

    CortesJO'BrienSKantarjianH. Discontinuation of imatinib therapy after achieving a molecular response. Blood2004;104:2204-2205.

  • 189

    RousselotPHuguetFReaD. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood2007;109:58-60.

    • Search Google Scholar
    • Export Citation
  • 190

    RossDMGriggASchwarerA. The majority of chronic myeloid leukaemia patients who cease imatinib after achieving a sustained complete molecular response (CMR) remain in cmr, and any relapses occur early [abstract]. Blood2008;112:Abstract 1102.

    • Search Google Scholar
    • Export Citation
  • 191

    MahonFXReaDGuilhotJ. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol2010:1029-1035.

    • Search Google Scholar
    • Export Citation
  • 192

    DarkowTHenkHJThomasSK. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics2007;25:481-496.

    • Search Google Scholar
    • Export Citation
  • 193

    MarinDBazeosAMahonFX. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol2010;28:2381-2388.

    • Search Google Scholar
    • Export Citation
  • 194

    NoensLvan LierdeMADe BockR. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood2009;113:5401-5411.

    • Search Google Scholar
    • Export Citation
  • 195

    IbrahimAREliassonLApperleyJF. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood2011;117:3733-3736.

    • Search Google Scholar
    • Export Citation
  • 196

    PartridgeAHAvornJWangPSWinerEP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst2002;94:652-661.

  • 197

    OsterbergLBlaschkeT. Adherence to medication. N Engl J Med2005;353:487-497.

  • 198

    Quintas-CardamaACortesJEKantarjianH. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma2008;8 (Suppl 3):S82-S88.

    • Search Google Scholar
    • Export Citation
  • 199

    KantarjianHMDeisserothAKurzrockR. Chronic myelogenous leukemia: a concise update. Blood1993;82:691-703.

  • 200

    SavageDGSzydloRMChaseA. Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol1997;99:30-35.

    • Search Google Scholar
    • Export Citation
  • 201

    SokalJEBaccaraniMRussoDTuraS. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol1988;25:49-61.

  • 202

    SwerdlowSHCampoEHarrisNL. WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4). Lyon, France:IARC;2008.

  • 203

    CortesJETalpazMO'BrienS. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer2006;106:1306-1315.

    • Search Google Scholar
    • Export Citation
  • 204

    DrukerBJ. Chronic Myelogenous Leukemia In: DeVitaVTLawrenceTSRosenburgSA eds. DeVita Hellman and Rosenberg's Cancer: Principles & Practice of Oncology. Vol. 2(ed 8): LippincottWilliams and Wilkins; 2007:2267-2304.

    • Search Google Scholar
    • Export Citation
  • 205

    ShahNP. Advanced CML: therapeutic options for patients in accelerated and blast phases. J Natl Compr Canc Netw2008;6 (Suppl 2):S31-S36.

    • Search Google Scholar
    • Export Citation
  • 206

    TalpazMSilverRTDrukerBJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood2002;99:1928-1937.

    • Search Google Scholar
    • Export Citation
  • 207

    PalandriFCastagnettiFAlimenaG. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica2009;94:205-212.

    • Search Google Scholar
    • Export Citation
  • 208

    KantarjianHMCortesJO'BrienS. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood2002;99:3547-3553.

    • Search Google Scholar
    • Export Citation
  • 209

    SawyersCLHochhausAFeldmanE. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood2002;99:3530-3539.

    • Search Google Scholar
    • Export Citation
  • 210

    PalandriFCastagnettiFTestoniN. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up. Haematologica2008;93:1792-1796.

    • Search Google Scholar
    • Export Citation
  • 211

    FavaCKantarjianHMJabbourE. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood2009;113:5058-5063.

    • Search Google Scholar
    • Export Citation
  • 212

    de LabartheARousselotPHuguet-RigalF. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood2007;109:1408-1413.

    • Search Google Scholar
    • Export Citation
  • 213

    YanadaMNaoeT. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma2006;47:1747-1753.

    • Search Google Scholar
    • Export Citation
  • 214

    ThomasDAFaderlSCortesJ. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood2004;103:4396-4407.

    • Search Google Scholar
    • Export Citation
  • 215

    ThomasDAO'BrienSMFaderlS. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) [abstract]. J Clin Oncol2010;28 (Suppl 15):Abstract 6506.

    • Search Google Scholar
    • Export Citation
  • 216

    RavandiFO'BrienSThomasD. First report of phase II study of dasatinib with hyperCVAD for the frontline treatment of patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Blood2010:2070-2077.

    • Search Google Scholar
    • Export Citation
  • 217

    RadichJ. Stem cell transplant for chronic myeloid leukemia in the imatinib era. Semin Hematol2010;47:354-361.

  • 218

    PavluJSzydloRMGoldmanJMApperleyJF. Three decades of transplantation for chronic myeloid leukemia: what have we learned?Blood2011;117:755-763.

    • Search Google Scholar
    • Export Citation
  • 219

    DaviesSMDeForTEMcGlavePB. Equivalent outcomes in patients with chronic myelogenous leukemia after early transplantation of phenotypically matched bone marrow from related or unrelated donors. Am J Med2001;110:339-346.

    • Search Google Scholar
    • Export Citation
  • 220

    HansenJAGooleyTAMartinPJ. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med1998;338:962-968.

    • Search Google Scholar
    • Export Citation
  • 221

    HorowitzMMRowlingsPAPasswegJR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant1996;17 (Suppl 3):S5-S6.

    • Search Google Scholar
    • Export Citation
  • 222

    GratwohlABrandRApperleyJ. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica2006;91:513-521.

    • Search Google Scholar
    • Export Citation
  • 223

    SausseleSLausekerMGratwohlA. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood2010;115:1880-1885.

    • Search Google Scholar
    • Export Citation
  • 224

    GoldmanJMMajhailNSKleinJP. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol2010;28:1888-1895.

    • Search Google Scholar
    • Export Citation
  • 225

    VelevNCortesJChamplinR. Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I. Cancer2010;116:3631-3637.

    • Search Google Scholar
    • Export Citation
  • 226

    JabbourECortesJSantosFP. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood2011;117:3641-3647.

    • Search Google Scholar
    • Export Citation
  • 227

    CrawleyCSzydloRLalancetteM. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood2005;106:2969-2976.

    • Search Google Scholar
    • Export Citation
  • 228

    GiraltSEsteyEAlbitarM. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood1997;89:4531-4536.

    • Search Google Scholar
    • Export Citation
  • 229

    GiraltSThallPFKhouriI. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood2001;97:631-637.

    • Search Google Scholar
    • Export Citation
  • 230

    McSweeneyPANiederwieserDShizuruJA. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood2001;97:3390-3400.

    • Search Google Scholar
    • Export Citation
  • 231

    OrRShapiraMYResnickI. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood2003;101:441-445.

    • Search Google Scholar
    • Export Citation
  • 232

    ChamplinRLimaMdKebriaeiP. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma2009;9 (Suppl 3):S261-S265.

    • Search Google Scholar
    • Export Citation
  • 233

    BeelenDWGraevenUElmaagacliAH. Prolonged administration of interferon-alpha in patients with chronicphase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood1995;85:2981-2990.

    • Search Google Scholar
    • Export Citation
  • 234

    GoldmanJMSzydloRHorowitzMM. Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood1993;82:2235-2238.

    • Search Google Scholar
    • Export Citation
  • 235

    MortonAJGooleyTHansenJA. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood1998;92:394-401.

    • Search Google Scholar
    • Export Citation
  • 236

    DeiningerMSchleuningMGreinixH. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica2006;91:452-459.

  • 237

    LeeSJKukrejaMWangT. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood2008;112:3500-3507.

    • Search Google Scholar
    • Export Citation
  • 238

    OehlerVGGooleyTSnyderDS. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood2007;109:1782-1789.

    • Search Google Scholar
    • Export Citation
  • 239

    JabbourECortesJKantarjianH. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity. Cancer2007;110:340-344.

    • Search Google Scholar
    • Export Citation
  • 240

    le CoutrePDHemmatiPNeuburgerS. Allogeneic stem cell transplantation (SCT) in advanced chronic myeloid leukemia (CML) patients after tyrosine kinase inhibitor (TKI) therapy [abstract]. Blood2008;112:Abstract 4419.

    • Search Google Scholar
    • Export Citation
  • 241

    ShimoniALeibaMSchleuningM. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia2009;23:190-194.

    • Search Google Scholar
    • Export Citation
  • 242

    BrecciaMPalandriFIoriAP. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib. Leuk Res2010;34:143-147.

    • Search Google Scholar
    • Export Citation
  • 243

    NicoliniFModoloLRausN. Allogeneic stem cell transplantation for blast crisis (BC) chronic myelogenous leukemia (CML) in the tyrosine kinase inhibitors (TKIs) era. Analysis of pre-transplant variables on transplant outcome. On behalf of the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire and the French Group of CML [abstract]. Blood2010;116:Abstract 2266.

    • Search Google Scholar
    • Export Citation
  • 244

    HehlmannRBergerUPfirrmannM. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood2007;109:4686-4692.

    • Search Google Scholar
    • Export Citation
  • 245

    RothMAntinJAshR. Prognostic significance of Philadelphia chromosome-positive cells detected by the polymerase chain reaction after allogeneic bone marrow transplant for chronic myelogenous leukemia. Blood1992;79:276-282.

    • Search Google Scholar
    • Export Citation
  • 246

    DelageRSoifferRDearKRitzJ. Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood1991;78:2759-2767.

    • Search Google Scholar
    • Export Citation
  • 247

    RadichJPGehlyGGooleyT. Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients. Blood1995;85:2632-2638.

    • Search Google Scholar
    • Export Citation
  • 248

    MackinnonSBarnettLHellerG. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant1996;17:643-647.

    • Search Google Scholar
    • Export Citation
  • 249

    OlavarriaEKanferESzydloR. Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood2001;97:1560-1565.

    • Search Google Scholar
    • Export Citation
  • 250

    RadichJPGooleyTBryantE. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients «late,» 18 months or more after transplantation. Blood2001;98:1701-1707.

    • Search Google Scholar
    • Export Citation
  • 251

    CostelloRTKirkJGabertJ. Value of PCR analysis for long term survivors after allogeneic bone marrow transplant for chronic myelogenous leukemia: a comparative study. Leuk Lymphoma1996;20:239-243.

    • Search Google Scholar
    • Export Citation
  • 252

    van RheeFLinFCrossNC. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant1994;14:609-612.

    • Search Google Scholar
    • Export Citation
  • 253

    KolbHJSchattenbergAGoldmanJM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood1995;86:2041-2050.

    • Search Google Scholar
    • Export Citation
  • 254

    LuznikLFuchsEJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control2002;9:123-137.

    • Search Google Scholar
    • Export Citation
  • 255

    GilleeceMHDazziF. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma2003;44:23-28.

    • Search Google Scholar
    • Export Citation
  • 256

    SimulaMPMarktelSFozzaC. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy. Leukemia2007;21:943-948.

    • Search Google Scholar
    • Export Citation
  • 257

    KantarjianHMO'BrienSCortesJE. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood2002;100:1590-1595.

    • Search Google Scholar
    • Export Citation
  • 258

    AnderliniPShethSlHicksK. Re: Imatinib mesylate administration in the first 100 days after stem cell transplantation. Biol Blood Marrow Transplant2004;10:883-884.

    • Search Google Scholar
    • Export Citation
  • 259

    DeAngeloDJHochbergEPAlyeaEP. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res2004;10:5065-5071.

    • Search Google Scholar
    • Export Citation
  • 260

    HessGBunjesDSiegertW. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol2005;23:7583-7593.

    • Search Google Scholar
    • Export Citation
  • 261

    CarpenterPASnyderDSFlowersMED. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood2007;109:2791-2793.

    • Search Google Scholar
    • Export Citation
  • 262

    WeisserMTischerJSchnittgerS. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica2006;91:663-666.

    • Search Google Scholar
    • Export Citation
  • 263

    PorkkaKKoskenvesaPLundanT. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood2008;112:1005-1012.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 127 120 13
PDF Downloads 25 23 0
EPUB Downloads 0 0 0